|
Variables
|
Tofacitinib (n = 70)
|
Abatacept (n = 70)
|
P
|
|---|
|
Age, years
|
69.2 ± 10.1
|
68.6 ± 12.1
|
0.925
|
|
Female, n, %
|
59 (84.3)
|
58 (82.9)
|
1.000
|
|
Disease duration, years
|
14.8 ± 14.0
|
14.1 ± 13.0
|
0.678
|
|
Stage I/II/III/IV, %
|
20.0/10.0/32.9/37.1
|
25.7/12.9/32.9/28.6
|
0.694
|
|
Class 1/2/3/4, %
|
5.7/71.4/22.9/0.0
|
5.7/68.6/25.7/0.0
|
0.956
|
|
BMI, kg/m2
|
21.4 ± 3.3
|
21.8 ± 2.8
|
0.505
|
|
SE copy number 0/1/2, %
|
31.4/61.4/7.1
|
28.6/54.3/17.1
|
0.252
|
|
Current smoker, n (%)
|
4 (5.7)
|
5 (7.1)
|
1.000
|
|
Ever smoker, n (%)
|
14 (20.0)
|
21 (30.0)
|
0.241
|
|
No. of prior biologic use
|
|
0 (biologic naïve )
|
31
|
37
|
0.398
|
|
1
|
13
|
14
|
0.830
|
|
2
|
14
|
7
|
0.098
|
|
≥ 3
|
12
|
12
|
1.00
|
|
MTX use, n (%)
|
41 (58.6)
|
40 (57.1)
|
1.000
|
|
MTX dose, mg/week
|
8.4 ± 2.4
|
8.0 ± 2.7
|
0.441
|
|
Oral corticosteroid use, n (%)
|
27 (38.6)
|
24 (34.3)
|
0.726
|
|
Oral corticosteroid dose, mg/daya
|
4.5 ± 2.8
|
5.5 ± 3.9
|
0.288
|
|
MMP-3, ng/mL
|
243.6 ± 242.9
|
153.4 ± 134.6
|
0.140
|
|
SJC, 0–28
|
4.4 ± 4.1
|
3.7 ± 3.7
|
0.507
|
|
TJC, 0–28
|
5.9 ± 5.0
|
5.4 ± 5.3
|
0.557
|
|
ESR, mm/h
|
40.1 ± 32.0
|
38.2 ± 30.2
|
0.882
|
|
CRP, mg/dL
|
1.54 ± 1.92
|
1.48 ± 2.19
|
0.742
|
|
RF, U/mL
|
217.7 ± 529.9
|
165.1 ± 375.8
|
0.790
|
|
ACPA, U/mL
|
245 ± 393.3
|
256.6 ± 293.8
|
0.323
|
|
GH, VAS 0–100 mm
|
53.1 ± 28.4
|
52.2 ± 24.2
|
0.777
|
|
EGA, VAS 0–100 mm
|
47.8 ± 20.4
|
45.2 ± 15.8
|
0.522
|
|
SDAI
|
21.9 ± 12.1
|
20.3 ± 11.4
|
0.283
|
|
CDAI
|
20.3 ± 11.2
|
19.8 ± 10.0
|
0.326
|
|
DAS28-ESR
|
4.8 ± 1.4
|
4.7 ± 1.3
|
0.508
|
|
HAQ-DI
|
1.12 ± 0.81
|
1.07 ± 0.76
|
0.689
|
- aPrednisolone equivalents
- Results are expressed as means ± SD unless otherwise stated
- Comparisons of matched groups were performed using the Student’s t test for continuous variables and Pearson’s χ2 test for categorized variables. ACPA anticitrullinated peptide antibody, BMI body mass index, CRP C-reactive protein, CDAI Clinical Disease Activity Index, DAS28-ESR Disease Activity Score in 28 joints using the erythrocyte sedimentation rate, EGA evaluator global assessment of disease activity, ESR erythrocyte sedimentation rate, GH patient’s global assessment of general health, HAQ-DI Health Assessment Questionnaire Disability Index, MMP-3, matrix metalloproteinase 3, MTX methotrexate, RF rheumatoid factor, SE shared epitope, SDAI Simplified Disease Activity Index, SJC swollen joint count, TJC tender joint count
